NeuroPace (NASDAQ:NPCE) Downgraded by JPMorgan Chase & Co. to “Neutral”

NeuroPace (NASDAQ:NPCE) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued on Friday, MarketBeat Ratings reports. They currently have a $9.00 target price on the stock. JPMorgan Chase & Co.‘s target price indicates a potential downside of 25.12% from the company’s current price.

Other equities analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of NeuroPace in a report on Wednesday, July 29th. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Mizuho started coverage on NeuroPace in a research report on Thursday, July 23rd. They set an “outperform” rating and a $22.00 target price on the stock. Raymond James Financial set a $21.00 target price on NeuroPace in a report on Tuesday, September 15th. Finally, Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.00.

NeuroPace Stock Down 4.0%

Shares of NeuroPace stock opened at $12.02 on Friday. NeuroPace has a one year low of $11.90 and a one year high of $19.60. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The stock’s 50-day moving average is $13.35 and its 200 day moving average is $14.79. The firm has a market cap of $412.53 million, a price-to-earnings ratio of -21.09 and a beta of 1.98.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The business had revenue of $22.83 million during the quarter, compared to the consensus estimate of $22.61 million. Equities research analysts anticipate that NeuroPace will post -0.67 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

Institutional investors and hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC lifted its position in NeuroPace by 16.3% in the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock valued at $45,464,000 after acquiring an additional 401,201 shares in the last quarter. BlackRock Inc. bought a new stake in NeuroPace during the 2nd quarter worth approximately $39,369,000. Deutsche Bank AG bought a new stake in NeuroPace during the 2nd quarter worth approximately $14,919,000. Algert Global LLC raised its stake in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after purchasing an additional 5,218 shares during the last quarter. Finally, Lazard Asset Management LLC raised its stake in shares of NeuroPace by 9.8% in the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock worth $1,635,000 after purchasing an additional 11,078 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Trending Headlines about NeuroPace

Here are a few of the latest headlines about NPCE:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.